- Describes a framework for the cardiovascular evaluation and management of patients undergoing HSCT
- Reveals the pathophysiology of HSCT, emphasizing therapeutic exposures and comorbidities
- Reviews existing cardiology and hematology/oncology guidleines to identify patients able to tolerate HSCT
This book discusses the epidemiology and the known cardiotoxic effects of chemoradiation agents in addition to newer therapies in hematopoietic stem cell transplantation (HSCT).
Recent expert consensus statements from cardiology and hematology/oncology societies are reviewed in regard to risk stratification of the patient based on the type of treatments they are undergoing. Finally, gaps in knowledge are identified with proposed avenues of research that allow for more accurate risk assessment, prediction and potential treatment of the HSCT patient in attenuating the risk of developing cardiovascular comorbidities.
Cardiovascular Considerations in Hematopoietic Stem Cell Transplantation reveals a picture of effective management of these patients in order to optimize both short- and long-term outcomes of HSCT. It is of considerable interest to all involved or training within this rapidly growing area of cardiology and oncology.
Table of Contents- HSCT at a glance.-
- Burden of cardiovascular disease in HSCT.-
- Risk factors and Mechanisms of Cardiotoxicity in HSCT.-
- Cardiotoxicity of commonly used drugs in HSCT.-
- Pre-HSCT cardiovascular evaluation.-
- Long Term Cardiotoxicity Surveillance in HSCT.-
- Cardiac Manifestations of Graft-Versus-Host Disease.-
- HSCT in low EF patients.-
- Hypertension in HSCT.-
- Diabetes Mellitus in HSCT.-
- Arrhythmias and conduction disorders in HSCT.-
- Coronary and peripheral arterial disease in HSCT.-
- Peripheral Arterial Disease in HSCT.-
- Thrombotic disease in HSCT.-
- Pulmonary hypertension in HSCT.-
- Pericardial disease in HSCT.-
- Metabolic syndrome in HSCT.-
- HSCT in patients with cardiac amyloidosis.-
- HSCT in patients with autoimmune conditions, sickle cell anaemia and thalassemia.-
- Cardiotoxicity surveillance and cardioprotective strategies in HSCT.
